Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 0.00 | -3.00K | -2.00K | -108.00K |
| Gross Profit | -- | 0.00 | 3.00K | 2.00K | 108.00K |
| SG&A Expenses | 23.43M | 11.99M | 9.36M | 7.64M | 6.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.77M | 30.14M | 24.09M | 22.41M | 22.49M |
| Operating Income | -41.77M | -30.14M | -24.09M | -22.41M | -22.49M |
| Income Before Tax | -37.92M | -26.49M | -21.42M | -20.86M | -21.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.92 | -26.49 | -21.42 | -20.86 | -21.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.92M | -26.49M | -21.42M | -20.86M | -21.75M |
| EBIT | -41.77M | -30.14M | -24.09M | -22.41M | -22.49M |
| EBITDA | -41.70M | -30.06M | -24.00M | -22.31M | -22.40M |
| EPS Basic | -1.44 | -1.23 | -1.23 | -3.53 | -6.10 |
| Normalized Basic EPS | -0.90 | -0.77 | -0.77 | -2.21 | -3.63 |
| EPS Diluted | -1.44 | -1.23 | -1.23 | -3.53 | -6.10 |
| Normalized Diluted EPS | -0.90 | -0.77 | -0.77 | -2.21 | -3.63 |
| Average Basic Shares Outstanding | 112.48M | 97.15M | 76.83M | 57.33M | 48.84M |
| Average Diluted Shares Outstanding | 112.48M | 97.15M | 76.83M | 57.33M | 48.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |